<DOC>
	<DOCNO>NCT00464919</DOCNO>
	<brief_summary>The prognosis patient metastatic locally advanced hepatocellular carcinoma ( HCC ) poor . The role conventional systemic chemotherapy limit chemotherapeutic agent in-effective relative toxic HCC patient tend poor organ function reserve due liver cirrhosis . The molecular-targeted therapy , aim derange signal pathway cancer cell microenvironment , hold promise HCC . Sorafenib ( BAY 43-9006 ) , novel bi-aryl urea , potent inhibitor VEGFR2 Raf kinase . The clinical activity sorafenib HCC test phase II study ( Bayer study 10874 ) , enrol total 137 advanced HCC patient . There 4 % document partial response , 5 % minor response , 55 % stable disease . The 6- month progression -free cohort 40 % . Currently , two on-going large-scale randomize trial sorafenib advanced HCC patient worldwide .</brief_summary>
	<brief_title>Sorafenib Plus Tegafur/Uracil ( UFUR® ) Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>The prognosis patient metastatic locally advanced hepatocellular carcinoma ( HCC ) poor . The role conventional systemic chemotherapy limit chemotherapeutic agent in-effective relative toxic HCC patient tend poor organ function reserve due liver cirrhosis . The molecular-targeted therapy , aim derange signal pathway cancer cell microenvironment , hold promise HCC . Sorafenib ( BAY 43-9006 ) , novel bi-aryl urea , potent inhibitor VEGFR2 Raf kinase . The clinical activity sorafenib HCC test phase II study ( Bayer study 10874 ) , enrol total 137 advanced HCC patient . There 4 % document partial response , 5 % minor response , 55 % stable disease . The 6- month progression -free cohort 40 % . Currently , two on-going large-scale randomize trial sorafenib advanced HCC patient worldwide.In study proposal , propose combine sorafenib metronomic chemotherapy treatment advance HCC patient . It recently demonstrate cytotoxic chemotherapy , give low-dose , continuous , uninterrupted way ( i.e . `` metronomic '' chemotherapy ) , inhibit tumor angiogenesis . The anti-angiogenesis effect metronomic chemotherapy potentiate combine inhibitor VEGF/VEGFR pathway . UFUR® , composite drug compose tegafur uracil , orally active 5-fluorouracil ( 5-FU ) preparation . The activity tegafur/uracil HCC test two relatively small-scale phase II study , objective tumor response rate range 0~18 % . Interestingly , tegafur metabolite , include γ-hydroxybutyric acid γ-butyrolactone , show potent inhibitor angiogenesis several preclinical model . Therefore , tegafur/uracil ( UFUR® ) , potential anti-HCC activity interest anti-angiogenesis activity , ideal candidate drug improve efficacy sorafenib HCC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Age &gt; 18 year ; ECOG PS 02 ; Histologically cytologically document unresectable and/or metastatic HCC ; Measurable disease RECIST criterion ; Previous local therapy complete &gt; 6 week ; Any acute toxicity ( CTCAE ) &lt; grade 1 ; ChildPugh A ; Liver transaminases ≤ 5 x ULN ; Albumin ≥ 2.8 g/dl ; Serum total bilirubin ≤ 3 mg/dl ; INR ≤ 2.3 PT ≤ 6 second control ; WBC ≥ 3,000/µl ; ANC ≥ 1,500/µl ; Platelets ≥ 100,000/µl ; Hb ≥ 8.5 g/dl ; Creatinine ≤ 1.5 x ULN ; AND Amylase lipase &lt; 1.5 x ULN Metastatic brain/leptomeningeal tumor ; Prior concomitant systemic anticancer treatment HCC , include : Systemic chemotherapy ( TACE allow ) Immunotherapy Hormonal therapy ( hormonal therapy use supportive use allow ) Rafkinase inhibitor MEK inhibitor Farnesyl transferase inhibitor VEGF/VEGFR inhibitor antiangiogenesis agent Investigational anticancer agent Severe and/or uncontrolled medical condition : Uncontrolled high blood pressure History poor compliance antihypertensive agent Active uncontrolled infection Unstable angina CHF MI CVA &lt; 6 month GI bleed &lt; 30 day Unable take oral medication Severe renal impairment require dialysis ; proteinuria &gt; grade 2 ; BMT stem cell rescue &lt; 4 month ; organ transplant ; HIV infection ; Major surgical procedure , open biopsy , significant traumatic injury &lt; 4 week receive minor surgical procedure ( e.g . core biopsy fine needle aspiration ) within 2 week ; Receive central venous line placement within 7 day ; Patients anticipate receive major surgery course study ; Use rifampin , St. John 's Wort [ Hypericum perforatum ] ; Patients take narrow therapeutic index medication monitor closely . These include warfarin , phenytoin , quinidine , carbamazepine , phenobarbital , cyclosporine , digoxin ; OR Patients tegafur contraindicate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Advance , hepatocellular carcinoma</keyword>
</DOC>